Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $1.1 million.

  • Spero Therapeutics' Change in Accured Expenses fell 7965.02% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 18578.44%. This contributed to the annual value of $11.2 million for FY2024, which is 56221.03% up from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Change in Accured Expenses is $1.1 million, which was down 7965.02% from -$1.5 million recorded in Q2 2025.
  • Spero Therapeutics' 5-year Change in Accured Expenses high stood at $5.3 million for Q3 2024, and its period low was -$9.5 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is -$233263.2, with a median of -$6000.0 in 2023.
  • Data for Spero Therapeutics' Change in Accured Expenses shows a peak YoY increase of 4003333.33% (in 2024) and a maximum YoY decrease of 96036.04% (in 2024) over the last 5 years.
  • Spero Therapeutics' Change in Accured Expenses (Quarter) stood at $5.3 million in 2021, then tumbled by 83.38% to $880000.0 in 2022, then crashed by 100.68% to -$6000.0 in 2023, then skyrocketed by 40033.33% to $2.4 million in 2024, then crashed by 54.84% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to -$1.5 million in Q2 2025 and -$9.5 million in Q1 2025.